September 16, 2024

Roflumilast Cream (Zoryve) for Atopic Dermatitis

Key Points

Key points are not available for this paper at this time.

Abstract

The FDA has approved a 0.15% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of mild to moderate atopic dermatitis (AD) in patients ≥6 years old. Roflumilast is the second PDE4 inhibitor to be approved in the US for treatment of AD; crisaborole (Eucrisa), which can be used in patients ≥3 months old, was the first.

KI fragen

Bookmark

Cite This Study

A Mon, study studied this question.

synapsesocial.com/papers/68e58488b6db643587521e16 https://doi.org/https://doi.org/10.58347/tml.2024.1711b

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Roflumilast Foam (Zoryve) for Seborrheic Dermatitis2024 · 2 citations
2Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children2024 · 60 citations
3639 - Efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients 2 to 5 years of age with mild to moderate atopic dermatitis (INTEGUMENT-PED): a phase 3 randomized controlled trial2024 · 3 citations
4Roflumilast Cream 0.15% in Patients with Atopic Dermatitis: Individual Patient Response from the Pooled INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Trials2024
5641 - Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials of adults and children with atopic dermatitis2024

KI fragen

Bookmark